Ozempic Safety Data: Deaths, Risk Factors, Clinical Evidence

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Direct deaths attributed solely to GLP-1 receptor agonists like Ozempic remain extremely rare in FDA post-market surveillance data. As of 2024, reported deaths involve complex comorbidities, medication interactions, or underlying cardiac conditions rather than GLP-1 monotherapy toxicity. Understanding actual risk versus perceived risk requires examination of clinical trial safety profiles, pharmacovigilance reports, and individual patient contexts.

Many patients considering GLP-1 therapy encounter alarming headlines without medical context. This creates confusion about real versus theoretical risks. PlexusDx supports precision wellness by combining baseline health screening, genetic predisposition assessment, and provider-guided medication selection—helping patients make informed decisions grounded in clinical evidence rather than fear-based narratives.

Actual Mortality Data: What FDA Surveillance Reveals

FDA MedWatch databases and post-market surveillance systems track adverse events reported by healthcare providers and patients. For GLP-1 receptor agonists, serious adverse events include pancreatitis, thyroid concerns, and gastroparesis—but direct attributable mortality from GLP-1 agents alone is exceedingly low. Most reported deaths involve patients with pre-existing cardiovascular disease, renal impairment, or polypharmacy complications.

Clinical trials for semaglutide and tirzepatide involved thousands of participants. The SELECT trial (semaglutide cardiovascular outcomes) enrolled 17,604 participants with obesity and cardiovascular disease; serious adverse events occurred at similar or lower rates than placebo in many categories. Transparency in trial reporting allows providers to contextualize risk for individual patients rather than generalizing from rare case reports.

Safety Comparison Framework: GLP-1 Therapy Across Clinical Evidence

Evaluating GLP-1 safety requires comparing documented adverse event rates in clinical trials against real-world outcomes. Below is a framework of commonly reported concerns versus actual prevalence data from major trials and post-market surveillance to support provider conversations.

Clinical Concern	Prevalence in Trials	Real-World Context
Pancreatitis	0.1–0.3% (varies by trial)	Often related to pre-existing gallstone disease or triglycerides >500 mg/dL
Gastroparesis	1–3% (nausea is much higher)	Usually mild, improves with dose titration; rarely requires discontinuation
Thyroid C-cell effects	Animal model signal only	No human thyroid cancer cases attributed to GLP-1 agonists in post-market data
Cardiovascular events	Lower or similar to placebo	SELECT trial showed 20% risk reduction in secondary outcomes; baseline screening essential
Acute kidney injury	<1% serious events	Risk higher in dehydrated patients; hydration counseling critical before starting

Who Requires Careful Pre-Treatment Medical Evaluation

Certain patient profiles warrant additional screening before GLP-1 initiation due to drug interactions or comorbidities. Relative contraindications include personal or family history of medullary thyroid cancer, Multiple Endocrine Neoplasia type 2, severe renal disease, active pancreatitis, or uncontrolled hypertension. Providers must also assess medication interactions, particularly with insulin or sulfonylureas.

Baseline laboratory work strengthens informed consent conversations. Lipid panels, liver and kidney function, fasting glucose, and calcitonin (if indicated) establish pre-treatment status. This allows providers to identify which patients benefit most from GLP-1 therapy versus those requiring alternative approaches. Regular follow-up monitoring of kidney function, lipids, and gastrointestinal symptoms ensures early detection of any adverse trends.

How to Evaluate GLP-1 Risk for Your Individual Health Profile

Patient safety depends on transparent communication with a qualified healthcare provider about personal and family medical history. Before starting any GLP-1 therapy—compounded or branded—disclose all medications, previous pancreatitis, gallstone disease, severe gastrointestinal disorders, thyroid conditions, and cardiovascular history. Provider assessment of this information, not media headlines, determines appropriate candidacy and dosing strategy.

Genetic predisposition screening can support these conversations by revealing how your peptide biology may influence medication response and side effect risk. Combined with baseline health metrics and provider guidance, this precision-wellness approach reduces guesswork and empowers patients to make decisions aligned with their actual medical needs rather than generalized population data.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test may help provide context by revealing predispositions in key peptide receptor genes (GIPR, MC4R) and metabolic pathways (FTO). These genetic markers do not predict exact medication response or guarantee side effect avoidance; instead, they support a more personalized conversation between you and your healthcare provider about which GLP-1 option aligns with your biology and goals.

The genetic test examines variants like GIPR rs1800437 and MC4R rs17782313—each influencing how your body may process peptide signaling. Understanding your genetic predispositions in these pathways can inform discussion of dosing strategy, potential side effect patterns, and whether a compounded formulation with flexible titration may be beneficial. This knowledge should be interpreted with a qualified healthcare provider, not as a standalone diagnostic tool.

When combined with baseline health screening and open provider dialogue, genetic context helps move beyond one-size-fits-all GLP-1 protocols. PlexusDx compounded semaglutide and tirzepatide options allow flexible dosing and formulation choice—giving providers and patients collaborative tools to optimize safety and efficacy based on individual medical history and genetic insights.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Does the post say any deaths have been attributed to Ozempic on its own?

No. The article says direct mortality attributable to GLP-1 agents alone is exceedingly low in FDA post-market surveillance. It states that reported deaths as of 2024 involve complex comorbidities, medication interactions, or underlying cardiac conditions rather than GLP-1 monotherapy toxicity, and that most involved patients with pre-existing cardiovascular disease, renal impairment, or polypharmacy complications.

What does the article's safety table say about the thyroid C-cell signal?

The table lists thyroid C-cell effects as an animal model signal only, and its real-world column states that no human thyroid cancer cases have been attributed to GLP-1 agonists in post-market data. That is the article's own characterization. It still lists a personal or family history of medullary thyroid cancer among the histories warranting extra screening before treatment.

Which patients does the post say face the highest acute kidney injury risk?

The table puts serious acute kidney injury under one percent and says risk runs higher in dehydrated patients, calling hydration counseling critical before starting. Elsewhere the article lists severe renal disease among conditions warranting additional screening, and recommends baseline kidney function testing plus follow-up monitoring of renal status during treatment to catch adverse trends early.

How large was the SELECT trial as this article describes it?

The post says SELECT, a semaglutide cardiovascular outcomes trial, enrolled 17,604 participants who had obesity and cardiovascular disease, and that serious adverse events occurred at similar or lower rates than placebo in many categories. Its table credits SELECT with a 20 percent risk reduction, though it labels that as a secondary outcome, which does not match how the trial's headline result is normally reported.

What baseline lab work does the article say strengthens informed consent?

It names lipid panels, liver and kidney function, fasting glucose, and calcitonin where indicated as the work that establishes pre-treatment status. The post argues this lets providers identify who benefits most versus who needs an alternative, and says follow-up monitoring of kidney function, lipids, and gastrointestinal symptoms allows early detection of adverse trends.

Related Reading

• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Maximus Glp 1
• Found Glp 1
• Orderly Meds Glp 1

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.